Homogeneous low-molecular-weight heparins with reversible anticoagulant activity

Yongmei Xu, Chao Cai, Kasemsiri Chandarajoti, Po Hung Hsieh, Lingyun Li, Truong Q. Pham, Erica M. Sparkenbaugh, Juzheng Sheng, Nigel S. Key, Rafal Pawlinski, Edward N. Harris, Robert J. Linhardt, Jian Liu

Research output: Contribution to journalArticlepeer-review

159 Scopus citations


Low-molecular-weight heparins (LMWHs) are carbohydrate-based anticoagulants clinically used to treat thrombotic disorders, but impurities, structural heterogeneity or functional irreversibility can limit treatment options. We report a series of synthetic LMWHs prepared by cost-effective chemoenzymatic methods. The high activity of one defined synthetic LMWH against human factor Xa (FXa) was reversible in vitro and in vivo using protamine, demonstrating that synthetically accessible constructs can have a critical role in the next generation of LMWHs.

Original languageEnglish (US)
Pages (from-to)248-250
Number of pages3
JournalNature Chemical Biology
Issue number4
StatePublished - Apr 2014

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Homogeneous low-molecular-weight heparins with reversible anticoagulant activity'. Together they form a unique fingerprint.

Cite this